In this study, we described the various suggested pathophysiologic mechanisms of the actions of SGLT2 inhibitors in NAFLD, Which might help in the up-regulation of effective fatty acid oxidation over carbohydrate oxidation, thereby leading to reduced hepatic steatosis and inflammation [26]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.